111 related articles for article (PubMed ID: 12353240)
1. Vaccination and melanoma risk.
Pfahlberg A; Botev IN; Kölmel KF; Gefeller O
Int J Cancer; 2002 Nov; 102(1):96-7. PubMed ID: 12353240
[No Abstract] [Full Text] [Related]
2. Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma.
Nishioka M; Tanemura A; Nishida S; Nakano A; Tsuboi A; Oji Y; Oka Y; Azuma I; Sugiyama H; Katayama I
Eur J Dermatol; 2012; 22(2):258-9. PubMed ID: 22240317
[No Abstract] [Full Text] [Related]
3. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control.
Krone B; Kölmel KF; Henz BM; Grange JM
Eur J Cancer; 2005 Jan; 41(1):104-17. PubMed ID: 15617995
[TBL] [Abstract][Full Text] [Related]
4. Melanoma vaccine momentum spurs interest, investment.
Fintor L
J Natl Cancer Inst; 2000 Aug; 92(15):1205-7. PubMed ID: 10922403
[No Abstract] [Full Text] [Related]
5. Prediction of response to anticancer immunotherapy using gene signatures.
Wang E; Bedognetti D; Marincola FM
J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
[No Abstract] [Full Text] [Related]
6. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
7. Melanoma vaccines: mixed past, promising future.
Ozao-Choy J; Lee DJ; Faries MB
Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
[TBL] [Abstract][Full Text] [Related]
8. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
9. [Unspecific immunological investigations in patients with malignant melanoma (author's transl)].
Knopf B; Wätzig V
Dermatol Monatsschr; 1982 Jan; 168(1):24-33. PubMed ID: 7044849
[No Abstract] [Full Text] [Related]
10. Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
Aris M; Bravo AI; Garcia Alvarez HM; Carri I; Podaza E; Blanco PA; Rotondaro C; Bentivegna S; Nielsen M; Barrio MM; Mordoh J
Front Immunol; 2019; 10():2213. PubMed ID: 31620131
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy with BCG as coadjuvant in the management of malignant melanomas].
Céspedes de Gómez MM; Aguilar Velázquez G; Valles de Cortés Y
Alergia; 1980 Apr; 27(2):69-86. PubMed ID: 7416444
[No Abstract] [Full Text] [Related]
12. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
[No Abstract] [Full Text] [Related]
13. [Medical therapy of malignant melanoma].
Mini E; Periti P
Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
[No Abstract] [Full Text] [Related]
14. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients.
Kölmel KF; Grange JM; Krone B; Mastrangelo G; Rossi CR; Henz BM; Seebacher C; Botev IN; Niin M; Lambert D; Shafir R; Kokoschka EM; Kleeberg UR; Gefeller O; Pfahlberg A
Eur J Cancer; 2005 Jan; 41(1):118-25. PubMed ID: 15617996
[TBL] [Abstract][Full Text] [Related]
15. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
16. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
17. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
18. [Possibilities of nonspecific immunotherapy with BCG in malignant melanomas of the skin].
Romano S; Ziccardi M; Muzio GF; Filippi B
Arch Maragliano Patol Clin; 1976; 32():114-21. PubMed ID: 802769
[No Abstract] [Full Text] [Related]
19. Vaccines and melanoma.
Ott PA; Fritsch EF; Wu CJ; Dranoff G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):559-69. PubMed ID: 24880947
[TBL] [Abstract][Full Text] [Related]
20. Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
Tarhini AA; Land S; Gupta A; Kirkwood JM
Nat Clin Pract Oncol; 2005 May; 2(5):240-1. PubMed ID: 16264957
[No Abstract] [Full Text] [Related]
[Next] [New Search]
